Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of September 11, 2026, ZBIO trades at $31.14 with a market cap of $2.03B and a P/E ratio of -2.65. ZBIO moved +0.11% today. Year to date, ZBIO is -9.80%; over the trailing twelve months it is +54.29%. Its 52-week range spans $5.83 to $44.60. Analyst consensus is strong buy with an average price target of $44.00. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ZBIO insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $31.14 |
| Market Cap | $2.03B |
| P/E Ratio | -2.65 |
| EPS | $-11.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.60 |
| 52-Week Low | $5.83 |
| Volume | 351.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $5.00M |
| Net Income | $-156.99M |
| Gross Margin | 0.00% |
4 analysts cover ZBIO: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.00.